Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition
- PMID: 31111585
- DOI: 10.1111/hel.12597
Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition
Abstract
Background: Since "Helicobacter pylori (H. pylori) infection" was set as the indication in the Japanese Society for Helicobacter Research (JSHR) Guidelines 2009, eradication treatment for H. pylori gastritis is covered under insurance since 2013 in Japan, and the number of H. pylori eradication has rapidly increased. Under such circumstances, JSHR has made the third revision to the "Guidelines for diagnosis and treatment of H. pylori infection" for the first time in 7 years.
Methods: The Guideline Committee held 10 meetings. Articles published between the establishment of the 2009 Guidelines and March 2016 were reviewed and classified according to the evidence level; the statements were revised on the basis of this review. After inviting public comments, the revised statements were finalized using the Delphi method.
Results: There was no change in the basic policy that H. pylori infectious disease is an indication for eradication. Other diseases presumed to be associated with H. pylori infection were added as indications. Serum pepsinogen level, endoscopic examination, and X-ray examination were added to the diagnostic methods. The effects of 1-week triple therapy consisting of potassium-competitive acid blocker (P-CAB), amoxicillin, and clarithromycin have improved, and high eradication rates can also be expected with proton pump inhibitors (PPI) or P-CAB combined with amoxicillin and metronidazole. If the susceptibility test is not performed, the triple PPI or P-CAB/amoxicillin/metronidazole therapy should be chosen, because the PPI/amoxicillin/metronidazole combination demonstrated a significantly higher eradication rate than PPI/amoxicillin/clarithromycin. In the proposal for gastric cancer prevention, we divided gastric cancer prevention measures by age from adolescent to elderly, who are at an increased gastric cancer risk, and presented measures for gastric cancer prevention primarily based on H. pylori eradication.
Conclusion: We expect the revised guidelines to facilitate appropriate interventions for patients with H. pylori infection and accomplish its eradication and prevention of gastric cancer.
Keywords: diagnosis; gastric cancer prevention; guidelines; indication; treatment.
© 2019 John Wiley & Sons Ltd.
Similar articles
-
Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.World J Gastroenterol. 2015 Jan 7;21(1):351-9. doi: 10.3748/wjg.v21.i1.351. World J Gastroenterol. 2015. PMID: 25574111 Free PMC article. Clinical Trial.
-
The updated JSPGHAN guidelines for the management of Helicobacter pylori infection in childhood.Pediatr Int. 2020 Dec;62(12):1315-1331. doi: 10.1111/ped.14388. Pediatr Int. 2020. PMID: 32657507 Free PMC article.
-
Guidelines in the management of Helicobacter pylori infection in Japan.Helicobacter. 2001 Sep;6(3):177-86. doi: 10.1046/j.1523-5378.2001.00027.x. Helicobacter. 2001. PMID: 11683920
-
Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study.Helicobacter. 2012 Aug;17(4):277-81. doi: 10.1111/j.1523-5378.2012.00943.x. Epub 2012 Mar 20. Helicobacter. 2012. PMID: 22759327 Clinical Trial.
-
Guidelines for the management of Helicobacter pylori infection in Japan: current status and future prospects.J Gastroenterol. 2007 Jan;42 Suppl 17:3-6. doi: 10.1007/s00535-006-1938-3. J Gastroenterol. 2007. PMID: 17238017 Review.
Cited by
-
Risk of Reflux-Related Symptoms and Reflux Esophagitis after Helicobacter pylori Eradication Treatment in the Japanese Population.J Clin Med. 2021 Apr 1;10(7):1434. doi: 10.3390/jcm10071434. J Clin Med. 2021. PMID: 33916067 Free PMC article.
-
Ten-day vonoprazan-based versus fourteen-day proton pump inhibitor-based therapy for first-line Helicobacter pylori eradication in China: A meta-analysis of randomized controlled trials.Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241286866. doi: 10.1177/03946320241286866. Int J Immunopathol Pharmacol. 2024. PMID: 39305222 Free PMC article.
-
Peri-Ulcerative Mucosal Inflammation Appearance is an Independent Risk Factor for 30-Day Rebleeding in Patients with Gastric Ulcer Bleeding: A Multicenter Retrospective Study.J Inflamm Res. 2022 Aug 30;15:4951-4961. doi: 10.2147/JIR.S378263. eCollection 2022. J Inflamm Res. 2022. PMID: 36065317 Free PMC article.
-
Commentary: Tailored therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.Front Pharmacol. 2022 Dec 20;13:1090776. doi: 10.3389/fphar.2022.1090776. eCollection 2022. Front Pharmacol. 2022. PMID: 36605400 Free PMC article. No abstract available.
-
Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan.Therap Adv Gastroenterol. 2023 May 2;16:17562848231168714. doi: 10.1177/17562848231168714. eCollection 2023. Therap Adv Gastroenterol. 2023. PMID: 37153499 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical